Stock Report: OncoGenex Pharmaceuticals Inc. (OGXI) Report Updated: Jun 17, 2013 | Print This Page

OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. The company’s products include Custirsen, which is in phase III clinical trials for the treatment of metastatic castrate resistant prostate cancer; and OGX-427, a product candidate in phase II clinical trials, which is designed to inhibit heat shock protein 27. Its pre clinical stage products include OGX-225 that is focused on reducing the production of insulin growth factor binding protein-2 (IGFBP) and IGFBP-5; and CSP-9222, a lead compound from a family of caspase activators. OncoGenex Pharmaceuticals, Inc. is headquartered in Bothell, Washington.